NEXMED

Mounjaro vs Wegovy: differences, results and how to choose (2026 guide)

A complete Mounjaro vs Wegovy comparison: mechanism, trial results, dose escalation, side effects, cost and how to choose between them.

Nexmed Editorial · Updated 11 September 2026
Mounjaro vs Wegovy: differences, results and how to choose (2026 guide)

Mounjaro (tirzepatide) and Wegovy (semaglutide) are the two most talked-about injectable weight-loss medicines. They are very similar, but they differ in mechanism, the size of the results seen in trials, the dosing schedule and cost. This guide compares them in detail, point by point, so you understand what sets them apart and how the choice between them is actually made.

In short: both are weekly injections that reduce appetite. Tirzepatide (Mounjaro) acts on two hormone receptors (GIP + GLP-1) and, in trials, has shown greater average weight loss than semaglutide 2.4 mg (Wegovy). However, there is no direct "head-to-head" comparison, and the right choice depends on your medical profile and your doctor's decision.

What they are and how they work

The fundamental difference between the two is their mechanism of action, and most of the other differences follow from it.

Wegovy (semaglutide): a GLP-1 agonist

Semaglutide mimics a single gut hormone, GLP-1, which is released naturally after meals. It acts on the appetite centers in the brain, reduces hunger, increases fullness and slows stomach emptying. The result: you eat less and feel full sooner.

Mounjaro (tirzepatide): a dual GIP/GLP-1 agonist

Tirzepatide is the first dual agonist: it acts on the receptors of two hormones at the same time, GIP and GLP-1. This combined action amplifies the effects on appetite and blood sugar control, which explains why, in trials, it produced greater average weight loss than single GLP-1 agonists.

How much weight you lose: trial results

This is the most searched-for difference, and also the easiest to misread.

Wegovy: the STEP 1 trial

In the STEP 1 trial (68 weeks), adults without diabetes treated with semaglutide 2.4 mg had an average weight loss of about 14.9% from baseline.

Mounjaro: the SURMOUNT-1 trial

In the SURMOUNT-1 trial (72 weeks), average weight loss was about 15% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg.

Why this is not a direct comparison

It is essential to remember that these figures come from different trials, with different populations and protocols, not from a head-to-head comparison. So even though tirzepatide appears superior in magnitude, the real difference for a given person may be smaller or larger. You can estimate an approximate trajectory with the Wegovy calculator and the Mounjaro calculator.

Dosing and dose escalation compared

Both are injected under the skin once a week, with a gradual dose increase to reduce gastrointestinal side effects.

The Wegovy schedule

Escalation takes 16 weeks: 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg (maintenance dose), 4 weeks at each step.

The Mounjaro schedule

It starts at 2.5 mg (starting dose), then increases by 2.5 mg at least every 4 weeks, up to a maximum of 15 mg, depending on response and tolerability.

In both cases, slow escalation is essential for tolerability. It is not rushed, and steps are not skipped.

Side effects: are they different?

The safety profile is similar. The most common effects are gastrointestinal (nausea, diarrhea, constipation, bloating), usually mild and temporary, and more pronounced when the dose is increased. High doses of tirzepatide may come with more gastrointestinal effects, but there is no tolerability difference that holds true for everyone. For details, see Wegovy and Mounjaro side effects.

Cost and availability

Both are prescription-only medicines, and prices vary by country, strength and pharmacy. Check the current cost with your pharmacy or insurer and plan for the full length of treatment.

Indications: who each one is for

  • Mounjaro (tirzepatide) is also indicated for type 2 diabetes, in addition to weight management, an advantage for patients with diabetes.
  • Wegovy (semaglutide 2.4 mg) is dedicated to chronic weight management.

This is an important distinction: for a patient with type 2 diabetes, tirzepatide may be the logical choice for medical reasons, not just for efficacy.

Benefits beyond weight loss

Both medicines have effects that go beyond simply reducing pounds. Through their mechanism, they improve blood sugar control, which is why tirzepatide is also used in type 2 diabetes. In trials, drugs in this class have also been associated with favorable effects on blood pressure, the lipid profile and some markers of cardiometabolic risk. These "side benefits" can matter in the doctor's decision, especially for patients with associated risk factors. Importantly, these effects are assessed individually, and the medicines are not given "for the heart" or "for blood pressure" outside their approved indications.

Long-term results and maintenance

An often-overlooked aspect is what happens after the maintenance dose is reached. Trials show that weight loss continues for several months, then tends to plateau. When treatment is stopped, some of the weight often comes back, because appetite increases again, which is an argument for a long-term approach combined with lifestyle changes. The difference between a short-lived result and a lasting one comes from adherence, diet (protein and fiber) and physical activity, not just the medicine itself.

Who should be cautious

Whichever you choose, there are situations in which these medicines are not indicated or require caution: a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, a history of pancreatitis, pregnancy and breastfeeding, and certain severe gastrointestinal conditions. These are assessed only by your doctor, not self-assessed.

How to choose between Wegovy and Mounjaro

There is no universal answer. The decision is made together with your doctor and takes several factors into account:

Medical profile

Type 2 diabetes, other conditions and your medical history can tip the balance toward one of the medicines.

Goals and realistic expectations

If the weight-loss target is large, high-dose tirzepatide has shown greater average results, but it takes patience during dose escalation.

Tolerability

How you react to gastrointestinal effects is individual. Sometimes the choice is adjusted based on how well you tolerate treatment.

Long-term cost

Treatment is long term, so the monthly cost matters in the decision. Compare current prices and budget accordingly.

Can you switch from one to the other?

Yes, but only on your doctor's recommendation, who decides the right starting dose of the new medicine. Do not switch treatment on your own initiative, and do not combine the two (they belong to the same class of incretin agonists).

Common myths

  • "Mounjaro is always better." Not necessarily: the size of the effect in trials differs, but the right choice is the one that fits your profile.
  • "If one doesn't work, I'll take both." False and risky: they are not combined.
  • "The results in ads are guaranteed." The numbers are trial averages; individual results vary widely.

How to read trial numbers correctly

When you read "~15% vs ~20.9%", it is easy to conclude that one medicine is "6% better". In reality, these percentages are averages: some patients lose much more, others much less. A percentage of body weight also means a different number of kilograms for each person: 15% of 120 kg (18 kg) is not the same as 15% of 80 kg (12 kg). In addition, the trials lasted different lengths of time (68 vs 72 weeks) and had different populations, so they cannot simply be laid on top of each other. The practical takeaway: use the numbers as an approximate reference, not as a promise. The best indicator for you remains your own response to treatment, assessed together with your doctor.

The impact on everyday life

Beyond the numbers, both medicines change your relationship with food: they reduce "food noise" (constantly thinking about food), lower cravings and make small portions feel like enough. Many patients describe a sense of control that conventional diets did not give them. This behavioral change, supported by treatment, is often the key to lasting results, as long as it is accompanied by healthy habits.

Whichever you take, a Wegovy and Mounjaro tracker such as Reko (partner app, iPhone) keeps your doses, titration schedule, side effects and weight in one place.

Conclusion

Wegovy and Mounjaro pursue the same goal, but by slightly different paths. Tirzepatide has shown greater weight loss on average, and Mounjaro is also indicated for diabetes. Semaglutide remains a solid, well-studied option. There is no "best" in the abstract; there is the best fit for you, decided together with your doctor based on your profile, goals, tolerability and cost. For an interactive comparison of the results, see Wegovy vs Mounjaro.

Frequently asked questions

Which leads to more weight loss, Wegovy or Mounjaro? In separate trials, tirzepatide (Mounjaro) showed greater average weight loss (~15–20.9%) than semaglutide 2.4 mg (Wegovy, ~14.9%). This is not a direct comparison, and individual results vary.

What is the difference in mechanism? Wegovy is a GLP-1 agonist; Mounjaro is a dual GIP + GLP-1 agonist, hence the larger average effects.

Which is cheaper? Prices vary by country, strength, pharmacy and insurance coverage. Check current prices before you buy.

Can they be combined? No. Two medicines from this class are not taken at the same time.

Can I switch from Wegovy to Mounjaro? Yes, but only on your doctor's recommendation, who decides the starting dose.

How do I choose? Based on your medical profile (including diabetes), goals, tolerability and cost, together with your doctor.

Read also


Educational content. It does not replace medical advice. Wegovy and Mounjaro are prescription medicines; eligibility, dosing and monitoring are decided by your doctor.

This article is for general information only and does not replace advice from your doctor or pharmacist. Do not start, stop or change a treatment without medical supervision.

More on weight loss & GLP-1